Tazemetostat Hydrobromide

氢溴酸他泽司他

Report date: 2026/04/07 20:00:20
NMEFirst In Class

Base Information

Drug NameTazemetostat Hydrobromide
Drug Alias NameTazemetostatum他托司他他泽司他他折司他Tazverik +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone-lysine N-methyltransferase EZH2 inhibitors
TargetsHistone-lysine N-methyltransferase EZH2
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLow-grade GliomaSolid tumours +[49] 
Global Approved IndicationsSarcomaLymphoma, Follicular
Approved Indications in ChinaLymphoma, Follicular
Original Approved Country/TerritoryUnited States
Original Approved Date2020/01/23
Country/TerritoryMainland China(BOAO LECHENG)BelgiumCanada +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEpizyme Inc
China Registration ClassN/A

Develop Information

Active CompaniesWeill Medical College of Cornell UniversityHutchmed (Hong Kong) LtdEpizyme Inc +[6] 
Inactive CompaniesHutchmed (China) LtdLoma Linda UniversityHutchison Medipharma Ltd
Active IndicationsPrimary mediastinal B cell lymphomaLow-grade GliomaSolid tumours +[40] 
Inactive IndicationsCytokine Release SyndromeRespiratory Distress Syndrome, AdultHepatic Insufficiency +[9] 

Other Information

ATC CodeL01
Related LinksWikipediaDrugBankKEGG